Bresnihan B, Cobby M
Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland.
Rheumatology (Oxford). 2003 May;42 Suppl 2:ii22-8. doi: 10.1093/rheumatology/keg329.
Interleukin-1 (IL-1) is a proinflammatory cytokine that plays a pivotal role in the pathophysiology of rheumatoid arthritis (RA). Inhibiting the activities of IL-1 at the receptor level with the recombinant human IL-1 receptor antagonist anakinra (Kineret; Amgen Inc., Thousand Oaks, CA) is a new therapeutic option for the management of patients with RA. Randomized, placebo-controlled trials have demonstrated that anakinra, alone and in combination with methotrexate, improves the signs and symptoms of RA. Anakinra also produces improvements in patient functionality and health-related quality of life, as measured by the Health Assessment Questionnaire and the Nottingham Health Profile, and reduces the number of productivity days missed due to illness. Furthermore, an initial study indicates that anakinra retards the progression of radiographic joint damage. Such clinical findings suggest that anakinra is an important addition to the rheumatology treatment armamentarium.
白细胞介素-1（IL-1）是一种促炎细胞因子，在类风湿关节炎（RA）的病理生理学中起关键作用。使用重组人IL-1受体拮抗剂阿那白滞素（Kineret；安进公司，加利福尼亚州千橡市）在受体水平抑制IL-1的活性是治疗RA患者的一种新的治疗选择。随机、安慰剂对照试验表明，阿那白滞素单独使用或与甲氨蝶呤联合使用，均可改善RA的体征和症状。通过健康评估问卷和诺丁汉健康量表测量发现，阿那白滞素还可改善患者功能和与健康相关的生活质量，并减少因病缺勤的天数。此外，一项初步研究表明，阿那白滞素可延缓影像学关节损伤的进展。这些临床研究结果表明，阿那白滞素是风湿病治疗药物中的重要补充。
